The FDA released AI drug development guidelines, with one AI-designed drug now in clinical trials.

A UK man becomes first to receive NHS-funded CAR-T therapy, beating aggressive leukemia.

MARS Bioimaging raised $15M to expand its portable, high-res color X-ray scanners using CERN tech.

China's AI tool detected 20 pancreatic cancers missed by CT scans, earning U.S. FDA breakthrough status.

A $25.8M UC San Diego project uses AI and 3D bioprinting to create patient-specific livers, aiming to solve the U.S. organ shortage.

Enliven Therapeutics reports promising Phase 1b results for ELVN-001 in treating resistant chronic myeloid leukemia, with 38% achieving major molecular response.

The FDA accepted Camurus’s resubmitted application for Oclaiz, a monthly acromegaly treatment, with a decision expected by June 10, 2026.

Erasca shares jumped 60% on merger rumors with AbbVie, then fell to $4.33 amid uncertainty.

CelLBxHealth names Peter Collins CEO and new directors, effective Jan. 31, to advance cancer diagnostics.

Futura Medical shares rose 11% after a small trial showed its WSD4000 gel significantly improved female sexual function.